by Raynovich Rod | Nov 29, 2017 | Biopharmaceuticals, Life Science ETF's and Mutual Funds, Macro
MegaCap Tech Stocks Take a Big Hit-Volatility Rising in a Sector Shift Market Rotation Supports Overall Market-S&P 500 Stable today up 17% YTD Sluggish Biotech Now Just a Market Performer With IBB up 17% YTD The booming tech sector sold off today with the XLK...
by Raynovich Rod | Sep 22, 2017 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Biotech Bull Market: XBI is leader for 2017 and Over Five Years The FBT First Trust Arca Outperformed Up 157% Over Five Years In 2016 the Sector Underperformed After the 2015 Downdraft Here is our July 2013 review of several top Life Science Funds and ETFs . Over five...
by Raynovich Rod | Aug 7, 2017 | 2023-24 Life Science Portfolios, Clinical Diagnostics and Tools
8/10 Red Screen in the Morning We cautioned on XBI at $78 on 7/31 and today it broke through support at $75 to $74.70. ======= 8/9 Update After Close: A Bit of Caution after Trump’s “Fire and Fury” Talk Investors are holding off as global risks rise...
by Raynovich Rod | Jan 13, 2016 | 2023-24 Life Science Portfolios, Clinical Diagnostics and Tools
Green Screen Alert Market Update…IBB up 4% today erasing most of Wednesday’s Losses but we are still down 13.86% for the five day period. Nasdaq rallied 1.97%. Rayno Biopharma top winners: ABBV up 6.56%, ALXN up 5.93%, AMGN up 5.29%,BIIB up 4.98%, REGN up...
by Raynovich Rod | Jan 12, 2016 | 2023-24 Life Science Portfolios
J.P.Morgan Conference: Relief Rally in Life Science Stocks After Rough Start to 2016 Green screen day with improved macro and healthcare sector leading Who knew biotech stocks traded with energy? Over the next few days we will review themes and companies from...
by Raynovich Rod | Nov 19, 2015 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Update-1 Rayno Recap for week of 11/20/15 IBB up 3.04%, XBI up 1.92%, XLV up 2.82% Notable Small Cap Winners Curis (CRIS) up 4.13%, Fibrocell Sciences (FCSC) up 3.42%, Geron (GERN) up 4.82%, Ignyta (RXDX) up 37.39%, and Ocera Therapeutics (OCRX) up 5.31%. Notable...
by Raynovich Rod | Oct 13, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Life Science ETF's and Mutual Funds
10/15 After the Close… XBI Up 7.26%…Green Screen…MOmentum is back Biotech stocks soared today in a broad rally showing a good appetite especially for small and mid-cap stocks. This could be a counter-trend rally in a biotech bear market but there is...
by Raynovich Rod | Sep 21, 2015 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Update-1… 9/22/15 …Biotech Stocks Trade Down Another Day Biotech stocks were weak tracking NASDAQ which was down 1.5%. The IBB was down 1.49% to $335.40 flat over one month and up 10.57% YTD. The August low was $325 and the IBB is 16% off July 20 highs....
by Raynovich Rod | Feb 10, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Life Science ETF's and Mutual Funds
Energy Stocks Down-Biotech and Healthcare Stocks Are Leaders NASDAQ Up 1.30% 4787 After a few days in the doldrums biotech stocks rallied across the board escaping the drag of macro news. Healthcare and technology sectors were among the leaders of the day moving...
by Raynovich Rod | Feb 4, 2015 | Life Science ETF's and Mutual Funds
Can Healthcare/Biotechnology Funds Outperform ETFs in 2015? In January of 2013 we compared three of the most liquid life science ETFs to some of the top mutual funds in the sector. Review our 2013 summary but the conclusion at that time was that ETFs provided better...